AngioDynamics: Palmetto GBA Finalizes Medicare Nanoknife Coverage from July 5, 2026

Author: Ceren Kaya…

AngioDynamics: Palmetto GBA Finalizes Medicare Nanoknife Coverage

AngioDynamics Inc (NASDAQ: ANGO) announced that Palmetto GBA has finalized Medicare coverage for Nanoknife IRE (Irreversible Electroporation), effective July 5, 2026. This decision will enhance access to this innovative cancer treatment technology for Medicare patients.

Details of the Decision

Palmetto GBA issued a final Local Coverage Determination (LCD) for Nanoknife IRE, covering the procedure starting July 5, 2026. AngioDynamics stated that this development is a significant step for the company's growth strategy and product portfolio.

Nanoknife Technology

Nanoknife is a minimally invasive treatment that targets cancer cells using electrical fields to destroy tumors while minimizing damage to healthy tissue. This coverage decision will facilitate access to this advanced therapy for Medicare beneficiaries.

Company Outlook

AngioDynamics expects this coverage decision to positively contribute to its revenues. The company continues to work on expanding the reach of Nanoknife technology to a broader patient population.

Impacted Symbols

Symbols affected by this headline and their sentiment signals

ANGOPositive

AngioDynamics, Inc.

Finalization of Medicare coverage will enable Nanoknife to reach a broader patient population, directly increasing AngioDynamics' revenues.

Impact score85%

The news, analyses, and comments on this platform do not constitute investment advice. When making investment decisions, you should conduct your own research and consult with a qualified financial advisor if necessary. FiNews cannot be held responsible for any losses that may arise from the use of this information.

More Headlines